Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX in Major Depressive Disorder
NCT02116361Phase 2Completed
- Sponsor
- Allergan
- Start
- Apr 2014
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of onabotulinumtoxinA in major depressive disorder (MDD), sponsored by Allergan. Started Apr 2014; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02116361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116361.